Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy

Cassie N. Kline,* Nancy M. Joseph,* James P. Grenert, Jessica van Ziffle, Eric Talevich, Courtney Onodera, Mariam Aboian, Soonmee Cha, David R. Raleigh, Steve Braunstein, Joseph Torkildson, David Samuel, Michelle Bloomer, Alejandra G. de Alba Campomanes, Anuradha Banerjee, Nicholas Butowski, Corey Raffel, Tarik Tihan, Andrew W. Bollen, Joanna J. Phillips, W. Michael Korn, Iwei Yeh, Boris C. Bastian, Nalin Gupta, Sabine Mueller, Arie Perry, Theodore Nicolaides, and David A. Solomon

Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of California San Francisco (UCSF), San Francisco, California (C.N.K., A.B., S.M., T.N.); Department of Pathology, UCSF, San Francisco, California (N.M.J., J.P.G., J.V.Z., T.T., A.W.B., J.J.P., I.Y., B.C.B., A.P., D.A.S.); Clinical Cancer Genomics Laboratory, UCSF, San Francisco, California (N.M.J., J.P.G., J.V.Z., E.T., C.O., I.Y., B.C.B., D.A.S.); Department of Radiology, UCSF, San Francisco, California (M.A., S.C.); Department of Neurological Surgery, UCSF, San Francisco, California (S.C., A.B., C.R., J.J.P., N.G., S.M., A.P., T.N.); Department of Radiation Oncology, UCSF, San Francisco, California (D.R.R., S.B.); Division of Pediatric Hematology/Oncology, UCSF Benioff Children’s Hospital Oakland, Oakland, California (J.T.); Division of Pediatric Hematology/Oncology, Valley Children’s Hospital, Madera, California (D.S.); Department of Ophthalmology, UCSF, San Francisco, California (M.B., A.A.C.); Division of Neuro-Oncology, Department of Neurological Surgery, UCSF, San Francisco, California (N.B.); Divisions of Gastroenterology and Medical Oncology, Department of Medicine, UCSF, San Francisco, California (M.K.)

Corresponding Authors: Theodore Nicolaides, MD, Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of California, San Francisco, 550 16th Street, Box 0434, San Francisco, CA 94143 (theodore.nicolaides@ucsf.edu). David A. Solomon, MD, PhD, Division of Neuropathology, Department of Pathology, University of California, San Francisco, Health Sciences West 451, 513 Parnassus Ave, San Francisco, CA 94143 (david.solomon@ucsf.edu).

*These authors contributed equally to this study.

Abstract

Background. Molecular profiling is revolutionizing cancer diagnostics and leading to personalized therapeutic approaches. Herein we describe our clinical experience performing targeted sequencing for 31 pediatric neuro-oncology patients.

Methods. We sequenced 510 cancer-associated genes from tumor and peripheral blood to identify germline and somatic mutations, structural variants, and copy number changes.

Results. Genomic profiling was performed on 31 patients with tumors including 11 high-grade gliomas, 8 medulloblastomas, 6 low-grade gliomas, 1 embryonal tumor with multilayered rosettes, 1 pineoblastoma, 1 uveal ganglioneuroma, 1 choroid plexus carcinoma, 1 chordoma, and 1 high-grade neuroepithelial tumor. In 25 cases (81%), results impacted patient management by: (i) clarifying diagnosis, (ii) identifying pathogenic germline mutations, or (iii) detecting potentially targetable alterations. The pathologic diagnosis was amended after genomic profiling for 6 patients (19%), including a high-grade glioma to pilocytic astrocytoma, medulloblastoma to pineoblastoma, ependymoma to high-grade glioma, and medulloblastoma to CNS high-grade neuroepithelial tumor with BCOR alteration. Multiple patients had pathogenic germline mutations, many of which were previously unsuspected. Potentially targetable alterations were identified in 19 patients (61%). Additionally, novel likely pathogenic alterations were identified in 3 cases: an in-frame RAF1 fusion in a BRAF wild-type pleomorphic xanthoastrocytoma, an inactivating ASXL1 mutation in a histone H3
Brain tumors are the most common pediatric solid malignancy and the second most common pediatric cancer, yet they exhibit some of the most stagnant survival curves. Diffuse intrinsic pontine gliomas (DIPGs) and supratentorial high-grade gliomas are only 2 examples that have shown little to no improvement after years of varying therapeutic approaches. Poor outcomes combined with long-term sequelae following radiation and/or cytotoxic chemotherapy have led investigators and providers to search for better prognostic indicators, predictors of response, and novel treatment strategies. Accordingly, a movement towards molecularly based diagnostic and treatment approaches has begun in recent years with a direction seemingly headed to personalized therapy for each patient. 

High-throughput sequencing has made possible the ability to molecularly profile patients and tumors at time of diagnosis, thus leading to cancer diagnoses and treatment beyond histopathology and traditional, standard-of-care therapies. Genomic profiling has been carried out across a multitude of pediatric CNS tumors, revealing targetable driver mutations and molecularly distinct tumor subtypes. Certainly, medulloblastoma is a prime example of how molecular profiling has improved risk stratification, prognostic prediction, and focused treatment strategies. As recently as 2007, medulloblastoma was classified by histology alone as classic, anaplastic, large cell, desmoplastic/nodular, or extensive nodularity. Genetic profiling has since led to a restructuring of medulloblastoma classification and by 2012, these tumors are now subclassified according to the molecular pathways that drive tumor development—Wnt pathway activated; SHH pathway activated; Group 3; and Group 4. Treatment approaches including recent clinical trials are now based on molecular subtypes, as this new system appears to better predict clinical outcomes than histology alone. Support for genetic profiling in pediatric cancer patients has been further bolstered by recent reports of a high frequency of pathogenic germline mutations in several pediatric neoplasms, particularly brain tumors. 

With these advancements, institutions are working to incorporate genomic profiling into routine patient care to improve diagnostic accuracy, better predict outcome, and personalize therapy. Our medical center is implementing these techniques in the pediatric neuro-oncology population and now has a year of practice in doing so. Herein we describe our experience using next-generation sequencing to diagnose and treat children with a variety of brain tumors and document how genomic profiling has significantly augmented the comprehensive nature of our treatment strategy.

### Methods

The 31 patients selected for sequencing represented a subset of the 100+ pediatric neuro-oncology patients who were either treated at UCSF Medical Center or seen for second opinion regarding treatment options during the study period. Cases selected for sequencing were chosen according to: (i) diagnostic uncertainty based on histology alone, (ii) diagnoses without successful standard-of-care therapeutic options, and (iii) tumors that progressed through prior therapies. Informed consent was obtained prior to genetic sequencing. This study was approved by the UCSF institutional review board.

Genomic DNA was extracted from peripheral blood and tumor tissue micro-dissected from formalin-fixed, paraffin-embedded blocks. Capture-based next-generation sequencing (NGS) was performed at the UCSF Clinical Cancer Genomics Laboratory, using an assay targeting the coding regions of 510 cancer-related genes, TERT promoter, select introns from 40 genes (for detection of gene fusions and other structural variants), and intergenic regions at regular intervals along each chromosome (for...
chromosomal copy number assessment), altogether with a total sequencing footprint of 2.8 Mb (UCSF500 Cancer Gene Panel, Supplementary Fig. 1). Sequencing libraries were prepared from genomic DNA with target enrichment performed by hybrid capture using a custom oligonucleotide library. Sequencing was performed on an Illumina HiSeq 2500. Duplicate sequencing reads were removed computationally to allow for accurate allele frequency determination and copy number estimates. The analysis was based on the human reference sequence UCSC build hg19 (NCBI build 37), using the following software packages: BWA, Samtools, Picard tools, GATK, CNVkit, Pindel, SATK, Annovar, Freebayes, Delly, and Nexus Copy Number (see Supplementary References 1–8). Single nucleotide variants and small insertions/deletions (indels) were visualized and verified using Integrated Genome Viewer. For samples with at least 25% tumor, >200x coverage for the tumor sample, and >100x coverage for the normal sample, the sensitivity is 99% and 83% and the specificity is 98% and 71% for fully clonal single nucleotide variants and small indels, respectively. Sensitivity of detection of copy number changes is >98% for samples with high tumor content. Large insertions, deletions, and gene rearrangements may be detected but have only been individually validated for select examples.

Molecular pathologists with specialization in neuropathology and brain tumor genetics organized results into formal reports, which detailed somatic and germline alterations as well as association with any known tumor predisposition syndromes, diagnostic or prognostic implications, and potential targeted therapies (example in Supplementary Fig. 2). Results were discussed at weekly multidisciplinary molecular tumor boards that included surgical and molecular pathologists together with oncologists, surgeons, and radiation oncologists from a wide variety of specialties.

**Results**

Between June 2015 and May 2016, genomic profiling was performed on 31 pediatric neuro-oncology patients (Table 1). Nineteen patients (61%) were male. Patient age ranged from 13 months to 19 years (median 9.6 y). Tumors included 11 high-grade gliomas, 8 medulloblastomas, 6 low-grade gliomas, 1 embryonal tumor with multilayered rosettes, 1 pineoblastoma, 1 uveal ganglioneuroma, 1 choroid plexus carcinoma, 1 metastatic chordoma, and 1 high-grade neuroepithelial tumor. Turn-around time from receipt of tumor tissue and peripheral blood to completion of formal report and discussion at molecular tumor board ranged from 14 to 21 days. The list of pathogenic alterations identified in the germline and tumor of each patient is presented in Table 1.

**Clarification of Pathologic Diagnoses**

The initial pathologic diagnosis was amended in 6 of 31 patients (19%) based on results of genomic profiling. Four of these cases are described below and illustrated in Fig. 1 to demonstrate how integrating the results of this genomic profiling with histologic and radiographic findings has improved diagnostic classification.

Patient 28 is a 9-year-old girl with a peripherally enhancing tectal mass with associated T2/ fluid attenuated inversion recovery (FLAIR) hyperintensity extending into bilateral thalami (Fig. 1A–B). Biopsy revealed an astrocytoma neoplasm with a few Rosenthal fibers and no high-grade histologic features (Fig. 1C). Immunohistochemical staining revealed intact expression of ATRX and no positivity with antibodies against BRAF-V600E, isocitrate dehydrogenase 1 (IDH1)-R132H, or histone H3-K27M mutant proteins. While the pathology was classified as an astrocytoma of indeterminate grade, imaging was thought to be more suggestive of a high-grade, infiltrative tumor. The patient was treated with focal irradiation and was receiving maintenance chemotherapy with temozolomide when genomic profiling was performed to clarify the diagnosis and identify therapeutic targets. Targeted sequencing revealed KIAA1549-BRAF gene fusion with no other genetic alterations. The pathologic diagnosis was amended to pilocytic astrocytoma, World Health Organization (WHO) grade I, and treatment with temozolomide was discontinued.

Patient 10 is an 18-month-old boy with progressive weakness and a solid, avidly enhancing mass centered in the midline of the posterior fossa (Fig. 1D). Histology revealed a primitive small blue cell tumor with high mitotic index (Fig. 1E–F), and an initial diagnosis of medulloblastoma, WHO grade IV, was rendered given presumed origin from the cerebellar vermis. Subsequent genomic profiling revealed somatic mutations including DICER1 frameshift and hotspot missense mutations, ARID1A frameshift mutation, and KDM5C missense mutation. No genetic alterations typical of medulloblastoma were identified. Based on this genomic profiling and recurrent DICER1 mutations that are known to be present in pilocytic astroblastoma, the preoperative imaging was re-reviewed showing an anatomic location superior to typical medulloblastoma cases, lack of visualization of the pineal gland, and mass effect on the subjacent cerebellar vermis. The diagnosis was subsequently amended to pilocytic astroblastoma, WHO grade IV.10

Patient 22 is an 11-year-old boy with a complex, solid, and cystic mass in the suprasellar region with dissemination along the right Sylvian fissure and spinal cord (Fig. 1G). Biopsy of a spinal cord metastasis demonstrated a mitotically active glial neoplasm with anuclear perivascular zones containing dense glial processes resembling perivascular pseudorosettes, initially interpreted as ependymoma by the referring pathologist (Fig. 1H). However, diffuse, strong immunostaining for oligodendrocyte transcription factor (OLIG2) was present in tumor cells (Fig. 1I), arguing against ependymoma. Genomic profiling revealed an activating missense mutation within the kinase domain of FGFR1 (p.K565E), which has been recurrently found in pilocytic astrocytomas and other pediatric low-grade gliomas.11,12 A molecularly integrated diagnosis of high-grade glioma with FGFR1 mutation was made, with one likely possibility being anaplastic transformation and dissemination from a pilocytic astrocytoma originating in the suprasellar region.

Patient 11 is a 4-year-old girl who was found to have a large, well-circumscribed mass in the right cerebellar hemisphere (Fig. 1J). Resection of the tumor demonstrated a solid, non-infiltrative malignant neoplasm composed of numerous
<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age</th>
<th>Site</th>
<th>Pathologic Diagnosis</th>
<th>Germline</th>
<th>Somatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>10</td>
<td>Posterior fossa</td>
<td>Medulloblastoma, classic</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>6</td>
<td>Posterior fossa</td>
<td>Medulloblastoma, nodular/desmoplastic</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>2</td>
<td>Posterior fossa</td>
<td>Medulloblastoma, nodular/desmoplastic</td>
<td>BRCA2 fs + fs (biallelic)</td>
<td>PTCH1 splice, GLI2 amp</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>5</td>
<td>Posterior fossa</td>
<td>Medulloblastoma, large cell/anaplastic</td>
<td>PALB2 non</td>
<td>PALB2 LOH</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>2</td>
<td>Posterior fossa</td>
<td>Medulloblastoma, nodular/desmoplastic</td>
<td>SUFU fs</td>
<td>SUFU LOH, KDM6A non</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>6</td>
<td>Posterior fossa</td>
<td>Medulloblastoma, nodular/non-desmoplastic</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>9</td>
<td>Posterior fossa</td>
<td>Medulloblastoma, nodular/desmoplastic</td>
<td>TP53 sub</td>
<td>TP53 LOH, PTCH1 non, PTEN del</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>8</td>
<td>Posterior fossa</td>
<td>Medulloblastoma, classic</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>3</td>
<td>L parietal lobe</td>
<td>Medulloblastoma, classic</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>1</td>
<td>Pineal region</td>
<td>Pineoblastoma</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>4</td>
<td>Posterior fossa</td>
<td>High-grade neuroepithelial tumor</td>
<td>None</td>
<td>BCOR exon 15 internal tandem dup</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>1</td>
<td>Pons</td>
<td>Embryonal tumor with multilayered rosettes</td>
<td>None</td>
<td>C19MC amp</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>4</td>
<td>Spinal cord, thoracic</td>
<td>Glioblastoma</td>
<td>MUTYH non</td>
<td>H3F3A K27M, ACVR1 sub, PIK3CA sub</td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>2</td>
<td>R frontal lobe</td>
<td>Glioblastoma</td>
<td>None</td>
<td>hypermutated including TP53, NF1, SETD2, ATRX, KDM6A, PTPN11, BRCA2</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>17</td>
<td>R frontal lobe</td>
<td>Glioblastoma</td>
<td>None</td>
<td>hypermutated including MSH6 fs, ATRX fs, TP53 sub, CDKN2A del, SETD2 fs, PDGFRα amp</td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>11</td>
<td>R thalamus</td>
<td>Glioblastoma</td>
<td>None</td>
<td>H3F3A K27M, TP53, BCORL1 non</td>
</tr>
<tr>
<td>17</td>
<td>F</td>
<td>10</td>
<td>L thalamus</td>
<td>Glioblastoma</td>
<td>None</td>
<td>AKT3 amp, CDK4 amp, MDM2 amp, PDGFRα amp + sub</td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>10</td>
<td>R parietal lobe</td>
<td>Glioblastoma</td>
<td>PMS2 non + del</td>
<td>hypermutated including MSH6 non, TP53 sub, PTEN sub, SETD2 non, NF1 non, ATRX fs</td>
</tr>
<tr>
<td>19</td>
<td>F</td>
<td>7</td>
<td>L temporal lobe</td>
<td>High-grade infiltrative astrocytoma</td>
<td>TP53 sub</td>
<td>TP53 LOH, PIK3CA sub</td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>15</td>
<td>Pons</td>
<td>High-grade infiltrative astrocytoma</td>
<td>MUTYH splice</td>
<td>MUTYH LOH, CDKN2A del, PDGFRα sub</td>
</tr>
<tr>
<td>21</td>
<td>M</td>
<td>12</td>
<td>Pons</td>
<td>Infiltrative astrocytoma, post-radiation therapy</td>
<td>None</td>
<td>PIK3CA sub, TP53 sub, ASXL1 non</td>
</tr>
<tr>
<td>22</td>
<td>M</td>
<td>11</td>
<td>Suprasellar w/ dissemination</td>
<td>High-grade glioma</td>
<td>None</td>
<td>FGFR1 sub</td>
</tr>
<tr>
<td>23</td>
<td>M</td>
<td>12</td>
<td>L temporal lobe</td>
<td>Diffuse astrocytoma</td>
<td>ERCC2 splice</td>
<td>IDH1 R132H, TP53 sub + fs</td>
</tr>
<tr>
<td>24</td>
<td>F</td>
<td>14</td>
<td>L frontal lobe</td>
<td>Diffuse astrocytoma, recurrent</td>
<td>None</td>
<td>IDH1 R132H, TP53 fs</td>
</tr>
<tr>
<td>25</td>
<td>M</td>
<td>12</td>
<td>L temporal lobe</td>
<td>Low-grade astrocytic neoplasm</td>
<td>None</td>
<td>MAP2K1 exon 2 small in-frame del</td>
</tr>
<tr>
<td>26</td>
<td>M</td>
<td>2</td>
<td>R frontal lobe</td>
<td>Oligodendrogioma</td>
<td>None</td>
<td>FGFR1 kinase domain dup</td>
</tr>
<tr>
<td>27</td>
<td>F</td>
<td>14</td>
<td>Posterior fossa w/ dissemination</td>
<td>Pilocytic astrocytoma</td>
<td>None</td>
<td>KIAA1549-BRAF fusion</td>
</tr>
<tr>
<td>28</td>
<td>F</td>
<td>9</td>
<td>Tectum/Midbrain</td>
<td>Pilocytic astrocytoma</td>
<td>None</td>
<td>KIAA1549-BRAF fusion</td>
</tr>
</tbody>
</table>
Identification of Pathogenic Germline Mutations

Eleven patients (35%) had pathogenic alterations identified in the germline, which were previously unsuspected in all but one medulloblastoma patient. While several of these germline mutations represent known associations in pediatric neuro-oncology such as TP53 mutation with choroid plexus carcinoma and SUFU mutation with medulloblastoma, multiple novel pathogenic germline alterations were discovered. These included MUTYH mutations in 2 children with diffuse midline gliomas, monoallelic PALB2 mutation in a child with medulloblastoma, and PTEN mutation in a child with uveal ganglioneuroma. Additional clinical details on the 11 patients with pathogenic germline alterations are presented in Table 2. Cases with novel pathogenic germline alterations are highlighted below and illustrated in Fig. 2, with additional select cases illustrated in Supplementary Fig. 4.

Two children with diffuse midline gliomas exhibited inactivating germline MUTYH mutations, which we recently reported and are briefly summarized here. Patient 13 is a 4-year-old boy with a subtotally resected glioblastoma from the thoracic spinal cord. Genomic profiling revealed a germline MUTYH nonsense mutation without detectable alteration of the remaining wild-type allele in the germline or tumor. Somatic mutations in the tumor included H3F3A p.K27M, ACVR1 p.G328E, and PIK3CA p.Q546K, which is the first example of an activating ACVR1 mutation occurring in a glioma arising outside of the pons. Patient 20 is a 15-year-old boy with a history of medulloblastoma at age 5 who was then found to have an expansile mass in the pons diagnosed as high-grade infiltrative astrocytoma, histone H3-K27 wild-type, on stereotactic biopsy. Genomic profiling revealed a germline MUTYH splice site mutation with loss of the remaining wild-type allele in the tumor. Also found in the tumor was homozygous deletion of CDKN2A and activating missense mutation in PDGFRA.

Patient 4 is a 5-year-old boy with a family history of breast cancer in both maternal and paternal lineages who was found to have an enhancing multinodular mass centered in the fourth ventricle and left cerebellar hemisphere (Fig. 2A). He underwent resection that demonstrated medulloblastoma with diffuse anaplasia and large cell histologic features (Fig. 2B–C). Genomic profiling was performed that identified a germline PALB2 nonsense mutation with loss of heterozygosity in the tumor, as well as numerous chromosomal copy number changes typical of tumors with defects in homologous recombination, including changes common to Group 3 medulloblastomas such as losses of 10q and 17p and gains of 1q and 17q (Fig. 2D). While biallelic germline PALB2 mutations are causative of Fanconi anemia and increased susceptibility to medulloblastoma and other pediatric malignancies, monoallelic PALB2 mutation in the germline has only been previously recognized to increase risk of breast, ovarian, and pancreatic carcinomas in adults.

Patient 30 is a 5-year-old girl with a history of macrocephaly and autism who underwent enucleation of a blind, painful eye after 2 years of unilateral refractory glaucoma of uncertain etiology. MR imaging of the orbits showed diffuse thickening of the uveal tract in the right globe (Fig. 2E). Pathology revealed expansion of the entire uveal tract, including the ciliary body and iris by an S-100 immunopositive spindle cell neoplasm containing scattered large dysmorphic ganglion cells, diagnostic of uveal ganglioneuroma (Fig. 2F–H). Genomic profiling revealed a germline PTEN nonsense mutation accompanied by loss of heterozygosity in the tumor, indicative of Cowden syndrome. A cavernous malformation in the left occipital lobe (Fig. 2I) and an arteriovenous malformation in the subcutis of the upper extremity and foot are also present in the patient. Family history is
**Fig. 1** Genomic profiling improves diagnostic accuracy. (A–C) Tectal glioma in a 9-year-old boy initially diagnosed as astrocytoma of uncertain grade found to have \textit{KIAA1549-BRAF} fusion leading to amended diagnosis of pilocytic astrocytoma, WHO grade I. (A) Axial T2-weighted FLAIR MR image revealing a tectal mass with extension into bilateral thalami. (B) Sagittal T1-weighted post-gadolinium MR image revealing peripheral enhancement and exophytic growth into the third ventricle with obstructive hydrocephalus. (C) Hematoxylin and eosin (H&E) stained section of the tumor. (D–F) Primitive neuroectodermal tumor in the midline of the posterior fossa of an 18-month-old boy initially diagnosed as medulloblastoma found to have \textit{DICER1} mutation leading to amended diagnosis of pineoblastoma. (D) Sagittal T2-weighted FLAIR MR image revealing a circumscribed solid mass centered in the midline within the region of the pineal gland causing compression of the subjacent cerebellar vermis. (E–F) H&E stained sections of the tumor. (G–I) Suprasellar mass with cerebrospinal dissemination in an 11-year-old boy initially diagnosed as ependymoma found to have \textit{FGFR1} mutation leading to amended diagnosis of high-grade glioma. (G) Coronal T1-weighted post-gadolinium MR image revealing a complex, solid, and cystic mass in the suprasellar space. (H) H&E stained section of the tumor. (I) Immunohistochemistry showing diffuse strong staining for OLIG2 in tumor cells. (J–L) High-grade neoplasm in the cerebellum of a 4-year-old girl initially diagnosed as medulloblastoma found to have internal tandem duplication within exon 15 of \textit{BCOR} leading to amended diagnosis of CNS high-grade neuroepithelial tumor with \textit{BCOR} alteration. (J) Coronal T2-weighted MR image. (K–L) H&E stained sections of the tumor. Sequencing reads containing the \textit{BCOR} internal tandem duplication are shown in Supplementary Fig. 3. Scale bar, 20 µm.
significant for early-onset uterine cancer in multiple individuals in the maternal lineage. The family has sought genetic counseling and initiated the recommended cancer screening given their newly identified tumor predisposition syndrome. To our knowledge, uveal ganglioneuroma has not been previously linked with Cowden syndrome.\(^{16}\)

### Identification of Potentially Targetable Alterations

One or more genetic alterations potentially targetable by currently available therapies were identified in 19 patients (61\%), listed in Table 3. The most frequently targetable mutations were activating \(\text{PIK3CA}\) missense mutations in high-grade gliomas known to increase sensitivity to mammalian target of rapamycin (mTOR) inhibitors such as everolimus, and amplification and/or activating missense mutations of \(\text{PDGFRA}\) in high-grade gliomas known to increase sensitivity to kinase inhibitors such as dasatinib.\(^{17}\) Other potentially actionable alterations included inactivating \(\text{PTCH1}\) mutations in medulloblastomas known to increase sensitivity to kinase inhibitors such as dasatinib.\(^{17}\) Several patients have initiated treatment with these targeted therapeutics, as part of clinical trials or through off-label prescription. Patient outcomes are being evaluated and will be reported in a follow-up study. Representative examples of patients whose tumors were identified to harbor potentially targetable alterations are highlighted in Supplementary Fig. 5.

Additionally, 3 patients had glioblastomas with high somatic mutational burden consistent with hypermutation, which has been shown to predict therapeutic benefit from programmed cell death protein 1 (PD-1) blockade (eg, nivolumab).\(^{18}\) One such case of exceptional interest (patient 18) is a 10-year-old boy with multiple café-au-lait macules but no other stigmata or family history consistent with neurofibromatosis. He was found to have a heterogeneously enhancing mass in the right parieto-occipital lobe, with pathology diagnostic of glioblastoma, WHO grade IV (Supplementary Fig. 6A–B). Genomic profiling revealed that the tumor had an exceptionally high mutational burden with greater than 700 somatic nonsynonymous mutations identified in the 510 genes targeted for sequencing, including mutations in several genes known to be important in gliomagenesis such as \(\text{TP53}, \text{PTEN}, \text{ATRX}, \text{NF1},\) and \(\text{SETD2}\). No pathogenic germline alterations were identified, although of note \(\text{PMS2}\) is not targeted for sequencing on the UCSF500 Cancer Gene Panel due to the presence of a pseudogene that interferes with

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age</th>
<th>Pathologic Diagnosis</th>
<th>Germline LOH in Tumor</th>
<th>Other Patient Hx</th>
<th>Significant Family Hx (# of affected members)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>F</td>
<td>2</td>
<td>Medulloblastoma</td>
<td>BRCA2 fs + fs (biallelic)</td>
<td>N/A</td>
<td>Fanconi anemia, medulloblastoma + Wilm’s tumor (x1)</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>5</td>
<td>Medulloblastoma</td>
<td>PALB2 non</td>
<td>yes</td>
<td>None</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>2</td>
<td>Medulloblastoma</td>
<td>SUFU fs</td>
<td>yes</td>
<td>None</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>9</td>
<td>Medulloblastoma</td>
<td>TP53 sub</td>
<td>yes</td>
<td>None</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>3</td>
<td>Choroid plexus carcinoma</td>
<td>TP53 sub, MSH6 fs</td>
<td>TP53 yes MSH6 no</td>
<td>None</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>4</td>
<td>Glioblastoma</td>
<td>MUTYH non</td>
<td>no</td>
<td>None</td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>10</td>
<td>Glioblastoma</td>
<td>PMS2 non + del (biallelic)</td>
<td>N/A</td>
<td>Café-au-lait macules, Paternal lineage: café-au-lait macules (x2)</td>
</tr>
<tr>
<td>19</td>
<td>F</td>
<td>7</td>
<td>High-grade astrocytoma</td>
<td>TP53 sub</td>
<td>yes</td>
<td>None</td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>15</td>
<td>High-grade astrocytoma</td>
<td>MUTYH splice</td>
<td>yes</td>
<td>Medulloblastoma at age 5, None</td>
</tr>
<tr>
<td>23</td>
<td>M</td>
<td>12</td>
<td>Diffuse astrocytoma</td>
<td>ERCC2 splice</td>
<td>no</td>
<td>None</td>
</tr>
<tr>
<td>30</td>
<td>F</td>
<td>5</td>
<td>Uveal ganglioneuroma</td>
<td>PTEN non</td>
<td>yes</td>
<td>None</td>
</tr>
</tbody>
</table>

Abbreviations: hx, history; sub, missense mutation; non, nonsense mutation; fs, frameshift mutation; splice, splice site mutation; LOH, loss of heterozygosity; del, deletion; ca, cancer
sequence alignment. Subsequent immunohistochemistry for mismatch repair proteins yielded intact expression of MLH1, MSH2, and MSH6, but no staining for PMS2 in tumor cells or nonneoplastic endothelial cells and lymphocytes (Supplementary Fig. 6C–F). Sanger sequencing of the \textit{PMS2} gene was performed on peripheral blood, revealing compound heterozygous mutations—a nonsense mutation and intragenic deletion of exon 4. The patient was diagnosed with constitutional mismatch repair deficiency (CMMRD) syndrome (OMIM #276300), and the family is currently being evaluated by medical genetics. Following completion of radiation therapy, the patient will begin immune checkpoint therapy with nivolumab, an agent that was recently shown to have remarkable activity in children with CMMRD syndrome.\textsuperscript{19}

Identification of Novel Pathogenic Alterations

In addition to highlighting known genetic drivers in pediatric neuro-oncology patients, this targeted sequencing approach has identified novel likely pathogenic alterations. The first example is a 12-year-old boy (patient 21) with DIPG lacking histone H3 mutation (Fig. 3A–C), an alteration that defines the vast majority of these tumors. Instead, genomic profiling revealed a somatic nonsense mutation in \textit{ASXL1}, which encodes an epigenetic regulator frequently mutated in pediatric acute myeloid leukemias.\textsuperscript{20}

Patient 25 is a 12-year-old boy with a low-grade astrocytic neoplasm in the left temporal lobe with a differential diagnosis after pathologic workup that included ganglioglioma and diffuse astrocytoma (Fig. 3D–F). Genomic profiling revealed a single somatic alteration in the tumor—a small in-frame

![Fig. 2](https://academic.oup.com/neuro-oncology/article-abstract/19/5/699/2514385)
deletion within exon 2 of MAP2K1 (Fig. 3K). Similar small
in-frame deletions within exon 2 of MAP2K1 were recently
reported in most Langerhans cell histiocytosis cases lacking
BRAF p.V600E mutation, where it functions as an alternate
mechanism of MAP kinase pathway activation.21,22 Given
the unresectable nature of this patient’s tumor and medi-
cally refractory seizures, targeted therapy with the MEK
inhibitor trametinib is being considered.
A final example is patient 29, a 19-year-old man with
recurrent pleomorphic xanthoastrocytoma with anaplastic
features in the left parietal lobe (Fig. 3G–J) that was found to be
BRAF wild-type by Sanger sequencing. He under-
go initial resection of pleomorphic xanthoastrocytoma
without anaplasia at 17 years of age and was followed with
serial imaging studies but no adjuvant therapy. Genomic
profiling of the recurrent tumor revealed a novel
- ATG7-RAF1 fusion (Fig. 3L), as well as homozygous deletion of
- CDKN2A in a child with uveal gangli-
oma, and monoallelic
- PTEN mutation in a child with uveal gangli-
oma, and monoallelic
- PALB2 inactivation
- SMARCB1 del
- H3F3A p.K27M
- AKT3 amp
- KIAA1549-BRAF fusion
- MAP2K1 exon 2 small in-frame del
- ATG7-RAF1 fusion
- CDK4 amp
- PALB2 inactivation
- PIK3CA sub
- PTCH1 inactivation
- PDGFRA amp or sub
- KIAA1549-BRAF fusion
- RAF1 exons 8–17 of
- CDKN2A
- ATG7
- MAP2K1
- AKT3
- MAP2K1 exon 2 small in-frame del
- ATG7-RAF1 fusion
- CDK4 amp
- SMARCB1 del
- PALB2 inactivation

### Discussion
Our experience at a Northern California tertiary medical
center illustrates that targeted genomic profiling on both
tumor and matched normal tissue at time of initial diagno-
sis or upon tumor recurrence is feasible and can have sig-
nificant impact on diagnosis, identification of unsuspected
germine mutations, and detection of potentially targetable
mutations in the pediatric brain tumor population. Among
our cohort of 31 pediatric neuro-oncology patients, 19%
had pathologic diagnosis amended after testing, 35% were
found to harbor a pathogenic germline mutation, and 61%
had potentially targetable genetic alterations identified.
As this cohort is small and contains a large fraction of high-
grade and recurrent tumors, the exact frequencies of cases
with pathogenic germline alterations is likely an over-
representation of all pediatric neuro-oncology patients.
Nonetheless, our findings highlight the need to consider
cancer-predisosing germline mutations in this population
even without notable family history and demonstrate the
utility of up-front genetic sequencing in terms of treatment
decision making and family counseling. Our experience
also demonstrates that a significant fraction of pediat-
tric neuro-oncology patients harbor potentially action-
able somatic alterations, although limitations of targeted
therapy such as penetration of the blood–brain barrier and
acquired resistance mechanisms must be recognized.
Additionally, our findings show that a targeted capture-
based sequencing assay can help to clarify diagnosis in
pediatric brain tumors, which are often challenging to
accurately classify. Other recent studies have shown that
molecular profiling using genome-wide DNA methylation
arrays can be a reliable and useful tool for aiding diagnos-
tic classification of pediatric brain tumors.13 However, the
utility of DNA methylation profiling as a solitary tool is lim-
ited in that it does not allow assessment of germline altera-
tions, somatic single nucleotide variants, or gene fusions.
In select cases, there may be advantages of performing
both DNA methylation profiling and targeted sequencing.
Noteworthy among our findings is the identification of
novel tumor-predisposing germline alterations, including
truncating MUTYH mutations in children with diffuse mid-
line gliomas, PTEN mutation in a child with uveal gangli-
oneuroma, and monoallelic PALB2 mutation in a child with
medulloblastoma. It remains unclear at present what the con-
tribution of these germline alterations are in all children with
these tumor types, but we speculate that future studies will
indeed confirm a role of MUTYH and PALB2 in pediatric gli-
oblastomas and medulloblastomas. Another novel finding was the

### Table 3
Potentially targetable genetic alterations identified

<table>
<thead>
<tr>
<th>Genetic Alteration</th>
<th>Targeted Agent</th>
<th>Tumor Type</th>
<th># of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIK3CA sub</td>
<td>mTOR inhibitor</td>
<td>Infiltrative astrocytoma</td>
<td>3</td>
</tr>
<tr>
<td>hypermutation</td>
<td>PD-1 inhibitor</td>
<td>Glioblastoma</td>
<td>3</td>
</tr>
<tr>
<td>PDGFRA amp or sub</td>
<td>dasatinib</td>
<td>Glioblastoma</td>
<td>3</td>
</tr>
<tr>
<td>KIAA1549-BRAF fusion</td>
<td>MEK inhibitor</td>
<td>Pilocytic astrocytoma</td>
<td>2</td>
</tr>
<tr>
<td>PTCH1 inactivation</td>
<td>SMO inhibitor</td>
<td>Medulloblastoma, nodular/desmoplastic</td>
<td>2</td>
</tr>
<tr>
<td>FGFR1 sub or kinase domain dup</td>
<td>kinase inhibitor</td>
<td>Low-grade glioma</td>
<td>2</td>
</tr>
<tr>
<td>H3F3A p.K27M</td>
<td>panobinostat</td>
<td>Diffuse midline glioma</td>
<td>2</td>
</tr>
<tr>
<td>AKT3 amp</td>
<td>mTOR inhibitor</td>
<td>Glioblastoma</td>
<td>1</td>
</tr>
<tr>
<td>MAP2K1 exon 2 small in-frame del</td>
<td>MEK inhibitor</td>
<td>Low-grade astrocytic neoplasm</td>
<td>1</td>
</tr>
<tr>
<td>ATG7-RAF1 fusion</td>
<td>MEK inhibitor</td>
<td>Pleomorphic xanthoastrocytoma</td>
<td>1</td>
</tr>
<tr>
<td>CDK4 amp</td>
<td>palbociclib</td>
<td>Glioblastoma</td>
<td>1</td>
</tr>
<tr>
<td>SMARCB1 del</td>
<td>EZH2 inhibitor</td>
<td>Chordoma</td>
<td>1</td>
</tr>
<tr>
<td>PALB2 inactivation</td>
<td>PARP inhibitor</td>
<td>Medulloblastoma</td>
<td>1</td>
</tr>
</tbody>
</table>

Abbreviations: sub, missense mutation; amp, amplification; dup, duplication; del, deletion; EZH2, enhancer of zeste homolog 2.
Fig. 3 Genomic profiling identifies novel likely pathogenic alterations. (A–C) Diffuse intrinsic pontine glioma in a 12-year-old boy lacking histone H3 mutation found to have a somatic inactivating mutation in ASXL1. (A) Axial T2-weighted FLAIR MR image. (B) Hematoxylin and eosin (H&E) stained section of the tumor showing an infiltrating astrocytoma without high-grade features. (C) Immunohistochemistry showing absence of staining for histone H3-K27M mutant protein. (D–G, K) Low-grade astrocytic neoplasm in a 12-year-old boy found to have small in-frame deletion within exon 2 of MAP2K1. (D) Coronal T2-weighted FLAIR MR image showing an ill-defined, expansile mass in the left medial temporal lobe. (E–F) H&E stained sections showing a low-grade astrocytic neoplasm with densely fibrillary background. (K) Sequencing reads for the tumor mapping to exon 2 of MAP2K1 with many containing an in-frame 15 bp deletion. (G–J, L) Recurrent pleomorphic xanthoastrocytoma with anaplastic features in a 19-year-old man lacking BRAF mutation found to have ATG7-RAF1 fusion. (G) Coronal T2-weighted FLAIR MR image showing a circumscribed mass in the superficial cortex of the left parietal lobe. (H) H&E stained section showing a solid neoplasm of pleomorphic astrocytes. (I) Periodic acid–Schiff stain showing one of the many eosinophilic granular bodies in the tumor. (J) Laidlaw reticulin stain demonstrating intercellular basement membrane deposition by the neoplastic astrocytes. (L) Genetic diagram of the ATG7 and RAF1 loci on chromosome 3, along with the inv(3)(p25.3;p25.2) identified in the tumor resulting in production of an in-frame fusion between exons 1–18 of ATG7 and exons 8–17 of RAF1 encoding the serine/threonine kinase domain. Scale bar, 20 µm.
identification of \( \text{IDH1} \) p.R132H mutation in 2 young children with diffuse astrocytomas (patients 23 and 24), an alteration that was previously known to occur only in diffuse gliomas of older adolescents and adults.\(^24\) Lastly, we demonstrate the utility of using a sequencing panel that covers a wide spectrum of cancer-associated genes, including those recurrently altered in non-CNS tumors, which enabled the identification of multiple novel likely pathogenic alterations in our cohort. We anticipate that these novel alterations (eg, \( \text{MAP2K1} \) small in-frame deletion in a low-grade astrocytic neoplasm) will prove to be recurrent mutations in pediatric brain tumors as genomic profiling continues in this population.

Moving forward, we aim to perform this genomic profiling on all pediatric brain tumor patients at our institution at time of diagnosis, with the goals of improving diagnostic accuracy, identifying therapeutically actionable alterations, offering appropriate guidance to families of patients with previously unknown germline mutations, and ultimately improving outcomes for affected children.

Supplementary Material

Supplementary material is available at Neuro-Oncology online.

Funding

No external funding was used to directly support this study.

Acknowledgments

C.N.K. is supported by NIH T32 grant (CA128583), Alex’s Lemonade Stand Foundation’s Pediatric Developmental Therapeutics Center of Excellence at UCSF (A120729) and UCSF-CTSI Strategic Opportunities Support Program (A119883). S.M. is supported by the NIH National Center for Advancing Translational Sciences through UCSF-CTSI (KL2TR000143). T.N. is supported by the Pediatric Brain Tumor Foundation, Frank A. Campini Foundation, and the National Cancer Institute (P50 CA097257). D.A.S. is supported by NIH Director’s Early Independence Award (DP5 OD021403) and Career Development Award from the UCSF Brain Tumor SPORE (P50 CA097257).

Conflict of interest statement. None for all contributing authors.

References


